Clinical Trial Update: Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab in combination with FOLFOXIRI and bevacizumab as first-line therapy for advanced colorectal cancer with RAS/BRAF mutations. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFOXIRI (folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, irinotecan)
• nivolumab (nivolumab)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED